Contributor Disclosures for Antiphospholipid Antibody Syndrome
Role Name Disclosure Details
Author Barry L Myones, MD, Associate Professor, Departments of Pediatrics and Immunology, Pediatric Rheumatology Section, Baylor College of Medicine; Director of Research, Pediatric Rheumatology Center, Texas Children's Hospital Nothing to discloseDetails
Coauthor Deborah McCurdy, MD, Consulting Staff, Department of Pediatrics, Division of Allergy/Immunology/Rheumatology, Mattel Children's Hospital, University of California at Los Angeles Nothing to discloseDetails
Medical Editor James M Oleske, MD, MPH, François-Xavier Bagnoud Professor of Pediatrics, Director, Division of Pulmonary, Allergy, Immunology and Infectious Diseases, Department of Pediatrics, New Jersey Medical School "no financial interest"Details
Pharmacy Editor Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc Pfizer Inc
Avanir Pharma
Details
Managing Editor David D Sherry, MD, Professor of Pediatrics, Division of Rheumatology, University of Pennsylvania; Director of Clinical Rheumatology, Children's Hospital of Philadelphia Nothing to discloseDetails
CME Editor Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine Baxter
Pfizer
Details
Chief Editor Steven R Neish, MD, SM, Director of Pediatric Cardiology Fellowship Program, Department of Pediatrics, Baylor College of Medicine Nothing to discloseDetails






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Barry L Myones

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication









Contributor Disclosure


Contributor:
Contributor Disclosure:
Deborah McCurdy, Coauthor  The contributor discloses no conflict of interest. 






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
James M Oleske

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

"no financial interest"
NoneNone 
Off label or investigational use of medication
"no financial interest"






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Mary L Windle

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Pfizer Inc
StockInvestment from broker recommendation 
Avanir Pharma
StockInvestment from broker recommendation 
Off label or investigational use of medication









Contributor Disclosure


Contributor:
Contributor Disclosure:
David D Sherry, Managing Editor  The contributor discloses no conflict of interest. 






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Daniel Rauch

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Baxter
HonorariaConsulting 
Pfizer
HonorariaConsulting 
Off label or investigational use of medication
none






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Steven R Neish

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication